| 1 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
|
| 2 |
ClinicalTrials.gov (NCT01933932) Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)
|
| 3 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 4 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5665).
|
| 5 |
Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
|
| 6 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
|
| 7 |
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
|
| 8 |
ClinicalTrials.gov (NCT03705507) International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
|
| 9 |
ClinicalTrials.gov (NCT01160718) Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
|
| 10 |
ClinicalTrials.gov (NCT03162627) Selumetinib and Olaparib in Solid Tumors
|
| 11 |
ClinicalTrials.gov (NCT02046850) To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
|
| 12 |
ClinicalTrials.gov (NCT00600496) A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
|
| 13 |
ClinicalTrials.gov (NCT01134601) A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
|
| 14 |
ClinicalTrials.gov (NCT01783197) Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
|
| 15 |
ClinicalTrials.gov (NCT00890825) AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
|
| 16 |
ClinicalTrials.gov (NCT01166126) Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
|
| 17 |
ClinicalTrials.gov (NCT02093728) To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
|
| 18 |
ClinicalTrials.gov (NCT02813135) European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
|
| 19 |
ClinicalTrials.gov (NCT03326310) Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
|
| 20 |
ClinicalTrials.gov (NCT02450656) Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
|
| 21 |
ClinicalTrials.gov (NCT03944772) Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
|
|
|
|
|
|
|
